Phase 3 N=120 Efficacy and Safety Evaluation in Recurrent Wheezing Attacks
Bronchospasm; Bronchiolitis · Bronchospasm; Bronchitis
Primary: Number of Recurrent Bronchospasm (Wheezing Attacks) — 299; 176 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=360 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 38; 13 Participants
Phase 3 N=374 Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
HIV Associated Diarrhea
Primary: Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose…
Phase 3 N=514 Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 16; 46; 49 Participants
Phase 3 N=242 Repeat Injection of Cingal® for Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Number of Treatment-Emergent Adverse Events: Cingal 13-02 vs. Cingal 13-01 — 73 Adverse events — p=0.3108
Phase 3 N=239 Bioequivalence Study for Benzyl Alcohol Lotion 5%.
Head Lice
Primary: Number of Participants With Infestation Successfully Eliminated by Active Treatment. — 59; 57; 6 Participants
Phase 3 N=369 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 49; 15 Participants
Phase 3 N=311 Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 32; 12 Participants
Phase 3 N=326 Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 38; 29 Participants
Phase 3 N=423 A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
Cystic Fibrosis
Primary: Mean Change in FEV1 (mL) From Baseline (Visit 1) Over the 26-week Treatment Period (to Visit 4). — 63; 8 mL — p=0.020
Phase 3 N=140 Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.
Scabies
Primary: Proportion of Patients That Are Identified as Cured. — 68; 70 Participants
Phase 3 N=91 Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Primary: Multifocal Electroretinography N1-P1 Amplitude — 3.6; 5.3; 4.9; 4.0 nV/deg^2
Phase 3 N=4,744 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 386; 502 Participants — p=<0.0001
Phase 3 N=90 Pain Reduction With Intranasal Medications for Extremity Injuries
Pain · Traumatic Limb Injury
Primary: Difference From Baseline in Visual Analog Scale Pain Score — -30.6; -31.9 score on a scale
Phase 3 N=75 Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation
Labor Pain
Primary: Time to Achieve an Adequate Epidural Level for Labor Analgesia — 7.0; 11.0; 8.5 minutes